Verily moves further into heart research as Study Watch picks up new FDA clearance

Verily Study Watch
Verily is looking to build solutions to help with screening, diagnosis and management of patients with atrial fibrillation. (Verily)

Alphabet's life sciences research arm Verily received FDA 510(k) clearance for its Study Watch to offer an irregular pulse monitor feature.

Verily plans to leverage this new capability to detect irregular heart rate to build solutions to help with screening, diagnosis, and management of patients with atrial fibrillation, the most prevalent irregular heartbeat, William Marks, M.D., head of clinical science at Verily, wrote in a blog post.

"This validates our approach at Verily to building robust, clinical-grade tools and solutions that can support clinicians in delivering the highest level of care and improve self-management for patients," Marks wrote.

Case Study

Across-the-Board Impact of an OB-GYN Hospitalist Program

A Denver facility saw across-the-board improvements in patient satisfaction, maternal quality metrics, decreased subsidy and increased service volume, thanks to the rollout of the first OB-GYN hospitalist program in the state.

A year ago, Verily's clinical wearable—which is not available to consumers—received clearance from the U.S. Food and Drug Administration (FDA) as a Class II medical device for its on-demand electrocardiogram feature.

RELATED: iRhythm links with Verily to help diagnose 'silent' afib cases

Verily has been working to research how best to gather health data on a wearable device. The company unveiled the Study Watch in April 2017 and positioned it as a clinical research tool.

Verily has been using it in a number of its own clinical research programs to collect biometric health information, including Project Baseline and the University of North Carolina and Harvard-led Aurora study.

Big pharmaceutical companies Novartis, Otsuka, Pfizer and Sanofi have also committed to using Verily's clinical wearable and broader Project Baseline platform.

In September, Verily announced a partnership with wearable ECG maker iRhythm Technologies to work on developing ways to better screen, diagnose and manage patients living with so-called “silent” afib, FierceBiotech reported.

IRhythm estimates that, of the patients who suffer a stroke due to afib, about 1 in 5 were previously unaware of their heart rhythm disorder. The company says more than 10 million people in the U.S. may be at high risk for the condition, with about one-third going undiagnosed.

RELATED: More wearables shift from fitness to clinical use with new Samsung and AT&T smartwatches

Verily said it plans to explore opportunities to leverage Study Watch as a measure of irregular pulse in clinical settings across its cardiovascular programs, including its collaboration with iRhythm.

As part of that collaboration, iRhythm contributes its wearable biosensor devices as well as its experience in artificial intelligence-based arrhythmia diagnosis alongside Verily's data analytics expertise.

"Cardiovascular research and care has long been an area of focus for Verily, as millions of patients are impacted by cardiovascular conditions in the US on a daily basis," Marks wrote in the blog post. "Our objective is clear: work together to develop best-in-class solutions for improved screening, diagnosis, and management of patients with AFib."

In the post, Marks said research will continue to be an important part of developing the right features for devices to inform better care and ultimately prevent disease.

"Through research, we have been able to hone Study Watch to better capture rich signals from the human body and generate evidence to support various disease management, treatments, and interventions," he said.

Smartwatches and devices that track heart health are a growing trend. The Apple Watch received FDA clearance in 2018 for its ECG feature, officially classifying it as a medical device capable of alerting its user to abnormal heart rhythms.

Wearables giant Fitbit, which Google plans to acquire, also plans to submit afib detection software to the FDA for regulatory review and approval, the company said in October.

Suggested Articles

A report shows that Medicaid managed care can save significantly more on drugs on than traditional Medicaid. Here are highlights from the analysis.

Blue Cross Blue Shield of Michigan now has 14 participants in its Blueprint for Affordability program. Here's what that model entails.

A healthcare non-profit wants to build a “moonshot factory” to bring data science and precision health to remote villages in the developing world.